Treatment of recurrent Clostridium difficile-associated disease (Q36304037)

13 August 2017

1 reference

title

Treatment of recurrent Clostridium difficile-associated disease (English)

1 reference

13 August 2017

main subject

Clostridium difficile

0 references

author

Christina M. Surawicz

series ordinal

1

object named as

Christina M Surawicz

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 November 2004

1 reference

Nature Reviews Gastroenterology & Hepatology

13 August 2017

published in

1 reference

13 August 2017

volume

1

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

32-38

1 reference

Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

Relapse versus reinfection withClostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

Molecular analysis of Clostridium difficile strains isolated from 18 cases of recurrent clostridium difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

Risk factors for early recurrent Clostridium difficile-associated diarrhea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

Oligosaccharide sequences attached to an inert support (SYNSORB) as potential therapy for antibiotic-associated diarrhea and pseudomembranous colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

Survival of Lactobacillus species (strain GG) in human gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

Bacteriotherapy for Clostridium difficile diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

Prevention of clindamycin-induced mortality in hamsters by Saccharomyces boulardii

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

Active and passive immunization against Clostridium difficile diarrhea and colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

Intravenous immunoglobulin therapy for severe Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

Intravenous metronidazole for the treatment of Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

Risk factors for recurrence of Clostridium difficile-associated diarrhea in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

Nosocomial acquisition of Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

Molecular analysis of relapse vs re-infection in HIV-positive patients suffering from recurrent Clostridium difficile associated diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

7 January 2021

The effect of probiotics on Clostridium difficile diarrhea

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

7 January 2021

Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

7 January 2021

Protection of hamsters against Clostridium difficile ileocaecitis by prior colonisation with non-pathogenic strains

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

7 January 2021

Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

7 January 2021

Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

7 January 2021

The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

7 January 2021

Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

7 January 2021

Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

7 January 2021

Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

7 January 2021

Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

7 January 2021

Whole-bowel irrigation as an adjunct to the treatment of chronic, relapsing Clostridium difficile colitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

7 January 2021

Environmental control to reduce transmission of Clostridium difficile

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

7 January 2021

Possible role of cross-transmission between neonates and mothers with recurrent Clostridium difficile infections

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0018

7 January 2021

Identifiers

DOI

10.1038/NCPGASTHEP0018

1 reference

13 August 2017

1 reference